Comparative Analysis of P73 and P53 Regulation and Effector Functions
Open Access
- 15 November 1999
- journal article
- research article
- Published by Rockefeller University Press in The Journal of cell biology
- Vol. 147 (4) , 823-830
- https://doi.org/10.1083/jcb.147.4.823
Abstract
P53 is mutated in ∼50% of human cancers, whereas mutations of the related p73 gene are rare. p73 can activate p53-responsive promoters and induce apoptosis when overexpressed in certain p53-deficient tumor cells. We show that p73 isoforms, p73α and p73β, can each induce permanent growth arrest with markers of replicative senescence when overexpressed in a tetracycline-regulatable manner in human cancer cells lacking functional p53. Human homologue of mouse double minute 2 gene product (hMDM2), but not an NH2-terminal deletion mutant, coimmunoprecipated with p73α or p73β, and inhibited p73 transcriptional activity as with p53. In contrast to p53, ectopically expressed hemagglutinin (HA)-tagged p73 proteins were not stabilized by treatment with several DNA damaging agents. Furthermore, unlike normal p53, which increases in response to DNA damage due to enhanced protein stability in MCF7 cells, endogenous p73 protein levels were not increased in these cells under the same conditions. Thus, although p73 has an ability, comparable to that of p53, to suppress tumor cell growth in p53-deficient cells, p73 induction is regulated differently from p53. These findings suggest that the selective pressures for p53 rather than p73 inactivation in tumors may reflect their differential responses to stresses such as DNA damage, rather than their capacities to induce permanent growth arrest or apoptosis programs.Keywords
This publication has 56 references indexed in Scilit:
- Mdm2 binds p73α without targeting degradationOncogene, 1999
- Regulation of p53 stability by Mdm2Nature, 1997
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- p53 in growth control and neoplasiaBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1996
- Clinical Implications of the p53 Tumor-Suppressor GeneNew England Journal of Medicine, 1993
- Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53Nature, 1993
- Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.Genes & Development, 1992
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992
- Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53Science, 1990
- Mutations in the p53 gene occur in diverse human tumour typesNature, 1989